Zolbetuximab-Vyloy Buying Guide: How to Get This New Gastric Cancer Targeting Drug

Zolbetuximab-Vyloy is the world's first monoclonal antibody drug targeting CLDN18.2, and its purchase channels and accessibility have attracted much attention from gastric cancer patients. At present, zotuximab has been approved for marketing in Japan, the United States, China and other countries and regions, but it has been on the market for a short time in China, and domestic patients are temporarily unable to purchase this drug through conventional channels.

For patients in urgent need of treatment, zotuximab can be obtained through participation in clinical trials-Vyloy. Currently, Astellas has launched a number of clinical trials in China for patients with CLDN18.2-positive gastric cancer. Patients can learn more by consulting a professional cancer hospital or visiting the relevant clinical trial registration platform. Participating in clinical trials not only provides early access to innovative drug treatments, but also allows you to receive treatment under the close monitoring of a professional medical team to ensure safety and effectiveness.

In addition, some patients may consider purchasing zotuximab overseas. However, there are certain risks associated with this approach, including issues with drug authenticity, shipping conditions, and legal compliance. Therefore, it is recommended that when considering purchasing drugs overseas, patients must consult a professional doctor or pharmacist and choose formal channels to ensure the safety and effectiveness of the drugs.

In general, although zotuximab has been on the market for a short time in China, patients still have the opportunity to obtain this innovative drug by participating in clinical trials or paying attention to official developments. With the continuous optimization of drug review and approval in China, it is believed that more patients will be able to benefit from this breakthrough treatment in the future. For patients with gastric cancer, keeping up to date with the latest treatment information and channels is an important step in improving their prognosis.

Reference: https://newsroom.astellas.us/2024-10-18-Astellas-VYLOY-TM-zolbetuximab-clzb-Approved-by-U-S-FDA-for-Treatment-of-Advanced-Gastric-and-GEJ-Cancer